Survodutide is an investigational dual glucagon and GLP-1 receptor agonist. On 1 October 2026 Boehringer Ingelheim reported that the Phase 3 SYNCHRONIZE-2 trial met both of its co-primary endpoints in adults with overweight or obesity and type 2 diabetes. The results were published the same day in the New England Journal of Medicine and presented at the European Association for the Study of Diabetes annual meeting in Milan. Survodutide is not approved in any market, including the UK. This is a report of trial results, not guidance of any kind.
What the trial was
SYNCHRONIZE-2 was a double-blind, placebo-controlled Phase 3 trial that randomly assigned 755 adults with overweight or obesity plus type 2 diabetes to weekly survodutide 3.6 mg, survodutide 6.0 mg, or placebo, for 76 weeks. The co-primary endpoints were the percentage change in body weight and the proportion of participants losing at least 5% of body weight. The design of this trial and of the companion SYNCHRONIZE-1 trial was pre-specified in a published rationale paper.
Two estimands, two different numbers
The same data are reported under two analyses, and the difference between them matters.
Under the efficacy estimand — which assumes participants remained on treatment — mean weight loss reached up to 13.1% against 3.1% with placebo, and up to 79.3% of treated participants lost at least 5% of body weight against 32.7% on placebo. The sponsor notes that those p values are nominal.
Under the treatment-regimen estimand, which counts outcomes regardless of whether participants stayed on treatment and is the analysis the journal publication emphasises, weight loss was 9.8% with 6.0 mg and 8.2% with 3.6 mg, against 3.9% with placebo.
Glycaemic control also improved. From a baseline HbA1c of 7.4%, levels fell by up to 1.21 percentage points against 0.03 with placebo, and up to 29.5% of treated participants reverted to normoglycaemia against 4.0%, under the efficacy estimand. Waist circumference fell by 11.1 cm against 3.5 cm on placebo. The HbA1c reduction is smaller than those reported for GLP-1-only and GIP/GLP-1 agents in diabetes populations; the trial was not designed to test that comparison.
The tolerability figure
Nausea, vomiting, diarrhoea and constipation were the most frequent adverse events and were mostly mild to moderate. Gastrointestinal events led 18% of survodutide recipients to discontinue, against 1.2% on placebo, usually during dose escalation. The sponsor attributes this in part to a rigid titration protocol and says newer trials allow more flexibility. The gap between the efficacy and treatment-regimen estimands is a direct consequence of that discontinuation rate, and it bears on how the result should be read.
Why the cross-trial comparison is not clean
Weight loss is generally smaller in people with type 2 diabetes than in people with obesity alone, which is why sponsors test the two populations separately. The companion SYNCHRONIZE-1 programme reported up to 16.6% mean weight loss at 76 weeks in adults with obesity without diabetes. SYNCHRONIZE-2 used only a placebo comparator, so its performance against approved incretin therapies is unknown.
Glucagon is usually associated with raising blood glucose, which made a diabetes trial a genuine test of the mechanism. The rationale is that a particular balance of glucagon and GLP-1 receptor agonism, alongside liver-fat reduction, may preserve glycaemic control while weight falls. An imaging substudy of 75 participants in SYNCHRONIZE-1 reported preferential loss of visceral and liver fat, with muscle accounting for no more than 10% of tissue lost. A Phase 2 dose-finding trial in adults without diabetes had previously reported up to 14.9% weight loss at 46 weeks against 2.8% with placebo.
Regulatory position
Survodutide holds US Breakthrough Therapy and European Medicines Agency PRIME designations for metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis. It is not approved in any market, and it holds no UK marketing authorisation. In the UK, medicines status is governed by the Medicines Act 1968 and the Human Medicines Regulations 2012; the MHRA's position is that a product presented with medicinal claims is a medicine regardless of any 'research use only' label. Cardiovascular outcomes data from SYNCHRONIZE-CVOT are expected later in 2026, and further Phase 3 trials in glycaemic control and MASH are ongoing.
What this is not
Nothing here describes a licensed therapy, and nothing here implies that any research peptide should be used by anyone. Survodutide remains an investigational compound; the trial results are reported for reference only, for research use.
This article is AI-researched and editorially reviewed. It is provided for research and educational purposes only and is not medical advice. Research peptides are not licensed for human consumption in the UK.